The effects of glucagon-like peptide-I (GLP-I) on hormone secretion from isolated human pancreatic islets.

Abstract

Glucagon-like peptide-I (GLP-I) is a potent incretin hormone that is now considered as a new therapeutic tool in the treatment of diabetes mellitus. In this study we characterized the effects of GLP-I on peptide hormone release from isolated human pancreatic islets. GLP-I stimulated insulin release in the presence of 10 mM glucose (2.8 mM glucose, 100%; 10 mM glucose, 166%; 10 mM glucose + 10 nM GLP-I, 222%) but had only a weak insulinotropic effect (128%) at 2.8 mM glucose. Glucagon release was inhibited by 10 mM glucose (2.8 mM glucose, 100%; 10 mM glucose, 72%) and by 10 nM GLP-I at 2.8 mM glucose (67%). Somatostatin secretion was increased by 10 mM glucose (2.8 mM glucose, 100%; 10 mM glucose, 166%). GLP-I stimulated somatostatin release in the presence of 2.8 mM glucose (172%). Pancreatic polypeptide (PP) secretion was enhanced by 10 mM glucose (2.8 mM glucose, 100%; 10 mM glucose, 236%). GLP-I induced PP release only in the presence of 2.8 mM glucose (184%).

• Authors: H C Fehmann, B J Hering, M J Wolf, H Brandhorst, D Brandhorst, R G Bretzel, K Federlin, B Göke
• Journal: Pancreas (Pancreas) Vol. 11 Issue 2 Pg. 196-200 (Aug 1995) ISSN: 0885-3177 [Print] United States
• PMID: 7479679 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Insulin
• Peptide Fragments
• Protein Precursors
• Somatostatin
• Pancreatic Polypeptide
• Glucagon-Like Peptide 1
• Glucagon
• Glucose

Topics

• Culture Techniques
• Glucagon (metabolism, pharmacology)
• Glucagon-Like Peptide 1
• Glucose (pharmacology)
• Humans
• Insulin (metabolism)
• Insulin Secretion
• Islets of Langerhans (drug effects, metabolism)
• Pancreatic Polypeptide (metabolism)
• Peptide Fragments (pharmacology)
• Protein Precursors (pharmacology)
• Somatostatin (metabolism)